Journal of Infection
Volume 60, Issue 5 , Pages 386-396 , May 2010

Listeria endocarditis in a patient with psoriatic arthritis on infliximab: Are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?

  • Theodoros Kelesidis

      Affiliations

    • Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    • Department of Medicine, Tufts University School of Medicine, Boston MA 02135, USA
    • Corresponding Author InformationCorresponding author at: Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, CHS 37-121, Los Angeles CA 90095, USA. Tel.: +1 310 825 7225; fax: +1 310 2080140.
    • ,
  • Amandeep Salhotra

      Affiliations

    • Department of Medicine, Tufts University School of Medicine, Boston MA 02135, USA
    • ,
  • Jorge Fleisher

      Affiliations

    • Department of Medicine, Tufts University School of Medicine, Boston MA 02135, USA
    • ,
  • Daniel Z. Uslan

      Affiliations

    • Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

,Accepted 12 February 2010.

References 

  1. http://www.fdable.com/aers/query/972d415847bf/7 [last visited 1/20/2010]. http://wwwfdablecom/aers/query/972d415847bf/7 [last visited 1/20/2010], 2010.
  2. Yamamoto M, Takahashi H, Miyamoto C, et al. A case in which the subject was affected by Listeria meningoencephalitis during administration of infliximab for steroid-dependent adult onset Still's disease. Nihon Rinsho Meneki Gakkai Kaishi. 2006;29(3):160–168
  3. Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol. 2005;16(5):289–292
  4. Tweezer-Zaks N, Shiloach E, Spivak A, Rapoport M, Novis B, Langevitz P. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha. Isr Med Assoc J. 2003;5(11):829–830
  5. Soderlin M, Blomkvist C, Dahl P, Forsberg P, Fohlman J. Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports. Lakartidningen. 2005;102(49):3794–3800
  6. Ramanampamonjy RM, Laharie D, Bonnefoy B, Vergniol J, Amouretti M. Infliximab therapy in Crohn's disease complicated by Listeria monocytogenes meningoencephalitis. Gastroenterol Clin Biol. 2006;30(1):157–158
  7. Osuna MR, Ferrer RT, Gallego GR, Ramos LM, Ynfante FM, Figueruela LB. Listeria meningitis as complication of treatment with infliximab in a patient with Crohn's disease. Rev Esp Enferm Dig. 2006;98(1):60–61
  8. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis?. Am J Gastroenterol. 2000;95(3):841–842
  9. Keulen ET, Mebis J, Erdkamp FL, Peters FP. Meningitis due to Listeria monocytogenes as a complication of infliximab therapy. Ned Tijdschr Geneeskd. 2003;147(43):2145
  10. Kesteman T, Yombi JC, Gigi J, Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol. 2007;26(12):2173–2175
  11. Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr. 2002;34(4):410–412
  12. Joosten AA, van Olffen GH, Hageman G. Meningitis due to Listeria monocytogenes as a complication of infliximab therapy. Ned Tijdschr Geneeskd. 2003;147(30):1470–1472
  13. Izbeki F, Nagy F, Szepes Z, Kiss I, Lonovics J, Molnar T. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease. Inflamm Bowel Dis. 2008;14(3):429–431
  14. Dederichs F, Pinciu F, Gerhard H, Eveld K, Stallmach A. Listeria meningitis in a patient with Crohn's disease–a seldom, but clinically relevant adverse event of therapy with infliximab. Z Gastroenterol. 2006;44(8):657–660
  15. de la Fuente PB, Marco PA, Riera MA, Boadas MJ. Sepsis caused by Listeria monocytogenes related with the use of infliximab. Med Clin (Barc). 2005;124(10):398
  16. Cabades OF, Vila FV, Arnal BM, Polo Sanchez JA. Lysteria encephalitis associated to infliximab administration. Rev Clin Esp. 2005;205(5):250
  17. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother. 2004;38(1):58–61
  18. Aparicio AG, Munoz-Fernandez S, Bonilla G, Miralles A, Cerdeno V, Martin-Mola E. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis Rheum. 2003;48(6):1764–1765
  19. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm county. Gut. 2004;53(6):849–853
  20. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48(2):319–324
  21. Gluck T, Linde HJ, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002;46(8):2255–2257
  22. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549
  23. Edelson BT, Unanue ER. Immunity to Listeria infection. Curr Opin Immunol. 2000;12(4):425–431
  24. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73(3):457–467
  25. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364(6440):798–802
  26. Mizuki M, Nakane A, Sekikawa K, Tagawa YI, Iwakura Y. Comparison of host resistance to primary and secondary Listeria monocytogenes infections in mice by intranasal and intravenous routes. Infect Immun. 2002;70(9):4805–4811
  27. Bitar AP, Cao M, Marquis H. The metalloprotease of Listeria monocytogenes is activated by intramolecular autocatalysis. J Bacteriol. 2008;190(1):107–111
  28. Elkington PT, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol. 2005;142(1):12–20
  29. Cordiali-Fei P, Trento E, D'Agosto G, et al. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J Autoimmune Dis. 2006;3:5
  30. Schluter D, Deckert M. The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect. 2000;2(10):1285–1292
  31. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285
  32. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–1265
  33. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–3412
  34. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford). 2007;46(2):327–334
  35. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis. 2006;65(Suppl. 3):iii2–15
  36. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003;42(5):617–621
  37. Stamm AM, Smith SH, Kirklin JK, McGiffin DC. Listerial myocarditis in cardiac transplantation. Rev Infect Dis. 1990;12(5):820–823
  38. Giunta G, Piazza I. Fatal septicaemia due to Listeria monocytogenes in a patient with systemic lupus erythematosus receiving cyclosporin and high prednisone doses. Neth J Med. 1992;40(3–4):197–199
  39. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001;28(6):1238–1244
  40. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516
  41. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35(5):883–890
  42. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245
  43. Antoni C, Krueger GG, de VK, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–1157
  44. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66(4):498–505
  45. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227–1236
  46. Antoni CE, Kavanaugh A, van der HD, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). J Rheumatol. 2008;35(5):869–876
  47. Southwick FS, Purich DL. Intracellular pathogenesis of listeriosis. N Engl J Med. 1996;334(12):770–776
  48. Fernandez Guerrero ML, Rivas P, Rabago R, Nunez A, de GM, Martinell J. Prosthetic valve endocarditis due to Listeria monocytogenes. Report of two cases and reviews. Int J Infect Dis. 2004;8(2):97–102

PII: S0163-4453(10)00052-6

doi: 10.1016/j.jinf.2010.02.009

Journal of Infection
Volume 60, Issue 5 , Pages 386-396 , May 2010

Article Tools

* Image Usage & Resolution